Cipla appoints Prabhakaran Balakrishnan Nair as Global Chief Manufacturing Officer
Mumbai: Cipla has announced the appointment of Prabhakaran Balakrishnan Nair, presently working as Chief of Quality - Indore plant, as Senior Management Personnel and Global Chief Manufacturing Officer of the Company w.e.f. 1st July, 2025.
Prabhakaran Balakrishnan Nair is a seasoned leader with over thirty-four years of extensive experience in manufacturing operations and quality management within the pharmaceutical industry.
Prior to joining Cipla, Prabhakaran was the Chief Operating Officer at Encube Ethicals, India. In this role, he was responsible for scaling up operations and product lines for the company including spearheading greenfield expansions for two sites at Goa and Indore.
Prior to this, he has held leadership roles at ACG Worldwide, Dr. Reddy'sLaboratories, IPCA Laboratories and Cadila Pharmaceuticals.
At Cipla, Prabhakaran is a Cluster Head in the Quality function and a member of the Cipla Leadership Group. He has been instrumental in fostering a strong quality culture through robust assurance frameworks and regulatory compliance initiatives. His expertise has strengthened the Global Quality Function through enhancing regulatory audit preparedness and integrating AI-driven technological advancements into quality operations. His leadership, combined with deep domain expertise in both manufacturing and quality, has helped sustain regulatory compliance, foster cross-functional collaborations, and drive superior value creation.
He holds a Master of Business Administration degree from Mumbai University (1992) and a Master of Pharmacy degree from Mumbai University (1988).
Read also: Cipla (EU), UK incorporates new wholly owned subsidiary in Germany
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.
